

1 AN ACT relating to biosimilar medicines.

2 ***Be it enacted by the General Assembly of the Commonwealth of Kentucky:***

3 ➔Section 1. KRS 304.17A-163 is amended to read as follows:

4 (1) As used in this section and KRS 304.17A-1631, unless the context requires
5 otherwise:

6 (a) "Clinical practice guidelines" means a systematically developed statement to
7 assist decision making by health care providers and patients about appropriate
8 healthcare for specific clinical circumstances and conditions;

9 (b) "Clinical review criteria" means the written screening procedures, decision
10 abstracts, clinical protocols, and clinical practice guidelines used by the
11 insurer, health plan, pharmacy benefit manager, or private review agent to
12 determine the medical necessity and appropriateness of health care services;

13 (c) "Health plan":

14 1. Means any state-regulated policy, certificate, contract, or plan that offers
15 or provides coverage in this state, by direct payment, reimbursement, or
16 otherwise, for prescription drugs pursuant to a step therapy protocol,
17 regardless of whether the protocol is described as a step therapy
18 protocol; and

19 2. Shall include but not be limited to a health benefit plan;

20 (d) "Pharmacy benefit manager" has the same meaning as in KRS 304.9-020;

21 (e) "Private review agent" has the same meaning as in KRS 304.17A-600;

22 (f) "Step therapy exception" means a determination that a step therapy protocol
23 should be overridden in favor of immediate coverage of the health care
24 provider's selected prescription drug; and

25 (g) "Step therapy protocol" means a protocol, policy, or program that establishes
26 the specific sequence in which prescription drugs that are for a specified
27 medical condition and medically appropriate for a particular insured are

1 covered by an insurer or health plan.

2 (2) (a) Except as provided in paragraph (b) of this subsection, clinical review criteria
3 developed by an insurer, health plan, pharmacy benefit manager, or private
4 review agent to establish a step therapy protocol shall be based on clinical
5 practice guidelines that:

6 1. Recommend that prescription drugs be taken in the specific sequence
7 required by the step therapy protocol;

8 2. Are developed and endorsed by a multidisciplinary panel of experts that
9 manages conflicts of interest among the members of the writing and
10 review groups by:

11 a. Requiring members to:

12 i. Disclose any potential conflict of interests with entities,
13 including insurers, health plans, and pharmaceutical
14 manufacturers; and

15 ii. Recuse himself or herself from voting if the member has a
16 conflict of interest;

17 b. Using a methodologist to work with writing groups to provide
18 objectivity in data analysis and ranking of evidence through the
19 preparation of evidence tables and facilitating consensus; and

20 c. Offering opportunities for public review and comments;

21 3. Are based on high quality studies, research, and medical practice;

22 4. Are created by an explicit and transparent process that:

23 a. Minimizes biases and conflicts of interest;

24 b. Explains the relationship between treatment options and outcomes;

25 c. Rates the quality of the evidence supporting recommendations;
26 and

27 d. Considers relevant patient subgroups and preferences; and

- 1 5. Are continually updated through a review of new evidence, research,
2 and newly developed treatments.
- 3 (b) In the absence of clinical practice guidelines that meet the requirements of
4 paragraph (a) of this subsection, an insurer, health plan, pharmacy benefit
5 manager, or private review agent may use peer-reviewed publications to
6 establish step therapy protocols.
- 7 (c) When establishing clinical review criteria for a step therapy protocol, an
8 insurer, health plan, pharmacy benefit manager, or private review agent shall
9 take into account the needs of atypical patient populations and diagnoses.
- 10 (d) 1. An insurer, health plan, pharmacy benefit manager, or private review
11 agent shall, upon written request, provide all specific written clinical
12 review criteria relating to a particular condition or disease, including
13 clinical review criteria relating to a step therapy exception
14 determination.
- 15 2. The clinical review criteria and other clinical information shall be made
16 available:
- 17 a. On the insurer's, health plan's, pharmacy benefit manager's, or
18 private review agent's website~~[Web site]~~; and
- 19 b. To a health care professional on behalf of an insured upon written
20 request.
- 21 (e) Nothing in this subsection shall be construed to require an insurer, health plan,
22 pharmacy benefit manager, or private review agent to establish a new entity to
23 develop clinical review criteria used for step therapy protocols.
- 24 (3) (a) When coverage of a prescription drug for the treatment of any medical
25 condition is restricted for use by an insurer, health plan, private review agent,
26 or a pharmacy benefit manager by a step therapy protocol, the insured and
27 prescribing provider shall have access to a clear, readily accessible, and

1 convenient process to request a step therapy exception.

2 (b) An insurer, health plan, private review agent, or pharmacy benefit manager:

3 1. May use its existing medical exceptions process to satisfy the
4 requirements of paragraph (a) of this subsection;

5 2. Shall make the step therapy protocol easily accessible on its
6 website~~[Web-site]~~; and

7 3. Shall, upon request, disclose all rules and criteria related to the step
8 therapy protocol to all prescribing providers, including the specific
9 information and documentation that must be submitted by a prescribing
10 provider or insured to be considered a complete request for a step
11 therapy exception.

12 (4) (a) A step therapy exception request, or an internal appeal under KRS 304.17A-
13 617 of a step therapy exception request denial, shall be granted by the insurer,
14 health plan, private review agent, or the pharmacy benefit manager within
15 forty-eight (48) hours if:

16 1. All necessary information to perform the step therapy exception review,
17 or make the appeal determination, has been provided; and

18 2. One (1) of the following apply:

19 a. The required prescription drug is:

20 i. Contraindicated or will likely cause an adverse reaction by
21 physical or mental harm to the insured; or

22 ii. Expected to be ineffective based on the known clinical
23 characteristics of the insured and the prescription drug
24 regimen;

25 b. Based on clinical appropriateness, the required prescription drug is
26 not in the best interest of the insured because the insured's use of
27 the required prescription drug is expected to:

- 1 i. Cause a significant barrier to the insured's adherence to or
2 compliance with the insured's plan of care;
- 3 ii. Worsen a comorbid condition of the insured; or
- 4 iii. Decrease the insured's ability to achieve or maintain
5 reasonable functional ability in performing daily activities;
- 6 c. The insured has tried the required prescription drug while under
7 the insured's current or a previous health plan, or another
8 prescription drug in the same pharmacologic class or with the
9 same mechanism of action, and the prescription drug was
10 discontinued due to lack of efficacy or effectiveness, diminished
11 effect, or an adverse event; or
- 12 d. The insured is stable on the prescription drug selected by the
13 insured's health care provider for the medical condition under
14 consideration while under a current or previous health plan.
- 15 (b) If a request for a step therapy exception, or an internal appeal under KRS
16 304.17A-617 of a step therapy exception request denial, is incomplete or
17 additional clinically relevant information is required, the insurer, health plan,
18 pharmacy benefit manager, or private review agent shall notify the prescribing
19 provider within forty-eight (48) hours of submission of the request or appeal:
- 20 1. That the request or appeal is incomplete; and
- 21 2. What additional or clinically relevant information is required in order to
22 approve or deny the step therapy exception.
- 23 (5) If a step therapy exception request determination, notification under subsection
24 (4)(b) of this section, or internal appeal determination under KRS 304.17A-617 of a
25 step therapy exception request denial by an insurer, health plan, pharmacy benefit
26 manager, or private review agent is not received by the prescribing provider within
27 the time period specified in subsection (4) of this section, the step therapy exception

1 request or internal appeal shall be deemed granted.

2 (6) An insured or a provider may:

3 (a) Initiate an internal appeal under KRS 304.17A-617 upon the denial of a step
4 therapy exception request under this section; and

5 (b) Request an external review under KRS 304.17A-623 upon the denial of an
6 internal appeal under paragraph (a) of this subsection.

7 (7) An insurer, health plan, pharmacy benefit manager, or private review agent shall:

8 (a) Upon the granting of a step therapy exception request, internal appeal, or
9 external review, authorize coverage for the prescription drug selected by the
10 insured's health care provider; or

11 (b) Upon the denial of a step therapy exception request or internal appeal, inform
12 the insured of the internal appeal or external review process, as applicable.

13 (8) (a) Except as provided in paragraph (b) of this subsection, the duration of any
14 step therapy protocol shall not be longer than a period of thirty (30) days if the
15 treatment is deemed and documented as clinically ineffective by the
16 prescribing provider.

17 (b) When the prescribing provider can demonstrate, through sound clinical
18 evidence, that the originally prescribed medication is likely to require more
19 than thirty (30) days to provide any relief or an amelioration to the insured,
20 the step therapy protocol may be extended up to seven (7) additional days.

21 (9) Nothing in this section shall be construed to prevent:

22 (a) An insurer, health plan, pharmacy benefit manager, or private review agent
23 from requiring:

24 ~~1. —~~ } an insured to try:

25 1. An AB-rated generic equivalent prior to providing coverage for the
26 reference listed drug; ~~or~~

27 2. An interchangeable biological product, as defined in 42 U.S.C. sec.

1 262(i)(3), prior to providing coverage for the reference product; or
 2 **3. A biosimilar biological product, as defined in 42 U.S.C. sec. 262(i)(2),**
 3 prior to providing coverage for the reference product;~~equivalent~~
 4 ~~branded prescription drug;~~
 5 unless the requirement meets any of the criteria set forth in subsection (4)(a)2.
 6 of this section pursuant to a step therapy exception request submitted under
 7 subsection (4) of this section;~~or~~
 8 **(b)~~2~~** **An insurer, health plan, pharmacy benefit manager, or private review**
 9 **agent from requiring** a pharmacist to effect substitutions of prescription drugs
 10 consistent with KRS 217.814 to 217.896 and 304.17A-535; or
 11 **(c)~~(b)~~** A health care provider from prescribing a prescription drug that is
 12 determined to be medically appropriate.

13 ➔Section 2. The General Assembly finds that increased access to biosimilar
 14 medicines has the potential to significantly reduce prescription drug costs. Biosimilar
 15 medicines are approved according to the same United States Food and Drug
 16 Administration standards of pharmaceutical quality, safety, and efficacy as their reference
 17 medications. Therefore, it is the intent of this Act to eliminate barriers impeding access to
 18 biosimilar medicines and the savings they can provide.